Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Yahoo Finance ·
If you're keeping an eye on gene-editing specialist CRISPR Therapeutics ( CRSP +2.47% ) , you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 million worth of this name in its flagship Ark Innovation ETF ( ARKK +3.66% ) and another $92 million worth in the smaller Ark Genomic Revolution ETF ( ARKG +3.34% ) . What is surprising is why Wood is holding it. Although patient-specific genomic repair remains a key part of this stock's bullish thesis, CRISPR Therapeutics' developmental work on another front has gone largely unnoticed and may not be reflected in the stock's price. CRISPR Therapeutics' founders essentially found a way of repairing damaged DNA with a corrected genetic sequence. It was the first company to ever win the FDA's approval for a gene-editing drug , in fact. That's Casgevy -- for the treatment of sickle cell disease -- which was approved in late 2023. Now the same patient-specific approach is being tested as a therapy for handful of other genetic diseases. The underlying science, however, isn't limited to a customized therapy for each patient. Gene editing can be used to create off-the-shelf treatments for all patients with a particular disease.
AI 시장 분석
Ark Investment, led by Cathie Wood, holds a massive stake in CRISPR Therapeutics (CRSP) worth a total of $362 million across its major ETFs. The market is focusing on customized gene therapies such as Casgevy, a sickle cell disease treatment approved by the FDA in late 2023. However, the potential of the company's upcoming off-the-shelf universal gene therapy development is not yet fully reflected in the stock price. Investors should pay attention to the ripple effect of universal gene editing technology beyond personalized treatments.
상승 영향
- Biotechnology — Ark Investment's massive $362 million investment and expectations for universal gene therapy development are stimulating investment sentiment across the biotech sector.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 61% · Bearish (Short) 39%
430 participants
Related News
- VAT Group AG GAAP EPS of CHF 3.30, revenue of CHF 511.9M
- Ondas Holdings secures $70M in new defense orders
- Norwood Financial GAAP EPS of $0.86 in-line, revenue of $29.3M beats by $1.2M
- J&J wins FDA nod for Ottava surgical robot
- HSBC upgrades Goldman Sachs, raises price target on Morgan Stanley
- SSAB AB (publ) GAAP EPS of SEK 2.09, revenue of SEK 27.49B
